Granted Patent
B2
US 12,582,712 · App. 17/814,221 · Granted Mar 24, 2026
Method of making anti-pro/latent myostatin antibodies
Inventors:
Gregory J. Carven (Maynard, MA); Michelle Straub (Yarmouth, ME); Adriana Donovan (West Roxbury, MA); Katherine Jane Turner (Acton, MA)
Assignee:
Scholar Rock, Inc.
A61K39/395A61K39/3955A61P21/04A61P21/06A61K2039/505A61K2039/545A61P9/00A61P21/00C07K14/475C07K16/22C07K2317/24C07K2317/33C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Aspects of the present disclosure relate to antibodies that specifically bind proMyostatin and/or latent Myostatin and uses thereof.
Claims (10)
1 . A method of making an antibody comprising:
(i) culturing a host cell comprising a polynucleotide or polynucleotides encoding an antibody comprising a heavy chain amino acid sequence of SEQ ID NO: 50 and a light chain amino acid sequence of SEQ ID NO: 51 under conditions sufficient to produce the antibody; and
(ii) purifying the antibody from the host cell.
2 . The method of claim 1 , further comprising confirming that the antibody inhibits proteolytic formation of mature myostatin by tolloid protease.
3 . The method of claim 1 , further comprising confirming that the antibody inhibits proteolytic formation of mature myostatin by tolloid protease with an IC50 of less than 1 μM.
4 . The method of claim 1 , further comprising formulating the antibody for intravenous administration.
5 . The method of claim 1 , further comprising formulating the antibody in a concentration suitable for administration at 0.3 to 30 mg/kg.
6 . The method of claim 1 , further comprising lyophilizing the antibody or formulating the antibody in an aqueous solution.
7 . The method of claim 1 , further comprising formulating the antibody in a pharmaceutical composition comprising at least one pharmaceutically acceptable carrier, excipient, or stabilizer.
8 . The method of claim 7 , wherein the at least one pharmaceutically acceptable carrier, excipient, or stabilizer comprises histidine.
Assignments (4)
SECURITY INTEREST
Recorded Mar 3, 2026
From: SCHOLAR ROCK, INC.
To: LSI FINANCING LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 075015/0854 →
CHANGE OF ASSIGNEE ADDRESS
Recorded Sep 16, 2025
From: SCHOLAR ROCK, INC.
To: SCHOLAR ROCK, INC.
Reel/Frame 072878/0561 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Dec 9, 2024
From: CARVEN, GREGORY J.; STRAUB, MICHELLE; DONOVAN, ADRIANA; TURNER, KATHERINE JANE
To: SCHOLAR ROCK, INC.
Reel/Frame 069525/0715 →
CHANGE OF ADDRESS OF ASSIGNEE
Recorded Dec 9, 2024
From: SCHOLAR ROCK, INC.
To: SCHOLAR ROCK, INC.
Reel/Frame 069548/0303 →
Continuity (4)
Continuation
15760393
Provisional Application
62219094
· Sep 15, 2015
References Cited (400)
US 3773919A
· Boswell et al.
· 1973
[cited by applicant]
US 4485045A
· Regen
· 1984
[cited by applicant]
US 4544545A
· Ryan et al.
· 1985
[cited by applicant]
US 4816397A
· Boss et al.
· 1989
[cited by applicant]
US 4816567A
· Cabilly et al.
· 1989
[cited by applicant]
US 5013556A
· Woodle et al.
· 1991
[cited by applicant]
US 5223409A
· Ladner et al.
· 1993
[cited by applicant]
US 5981568A
· Kunz et al.
· 1999
[cited by applicant]
US 6096506A
· Lee et al.
· 2000
[cited by applicant]
US 6172197B1
· Mccafferty et al.
· 2001
[cited by applicant]
US 6291158B1
· Winter et al.
· 2001
[cited by applicant]
US 6582915B1
· Griffiths et al.
· 2003
[cited by applicant]
US 6593081B1
· Griffiths et al.
· 2003
[cited by applicant]
US 6656475B1
· Lee et al.
· 2003
[cited by applicant]
US 6696245B2
· Winter et al.
· 2004
[cited by applicant]
US 6858208B2
· Lee et al.
· 2005
[cited by applicant]
US 7083784B2
· Dall'acqua et al.
· 2006
[cited by applicant]
US 7138501B2
· Ruben et al.
· 2006
[cited by applicant]
US 7566768B1
· Lee et al.
· 2009
[cited by applicant]
US 20030167492A1
· Lee et al.
· 2003
[cited by applicant]
US 20060216279A1
· Glass et al.
· 2006
[cited by applicant]
US 20070178095A1
· Smith et al.
· 2007
[cited by applicant]
US 20090031435A1
· Stockwell et al.
· 2009
[cited by applicant]
US 20100331252A1
· Hamrick et al.
· 2010
[cited by applicant]
US 20110239317A1
· Lee et al.
· 2011
[cited by applicant]
US 20110256132A1
· Ashman et al.
· 2011
[cited by applicant]
US 20130065820A1
· Bower et al.
· 2013
[cited by applicant]
US 20140017262A1
· Sanicola-Nadel et al.
· 2014
[cited by applicant]
US 20160199458A1
· Knopf et al.
· 2016
[cited by applicant]
US 20210283166A1
· Long et al.
· 2021
[cited by applicant]
US 20220106390A1
· Donovan et al.
· 2022
[cited by applicant]
US 20240002490A1
· Nomikos et al.
· 2024
[cited by applicant]
US 20240368262A1
· Long et al.
· 2024
[cited by applicant]
US 20240391989A1
· Donovan et al.
· 2024
[cited by applicant]
AU 2011244851A1
· 2011
[cited by applicant]
CN 103097415A
· 2013
[cited by applicant]
EP 0171496A2
· 1986
[cited by applicant]
EP 0173494A2
· 1986
[cited by applicant]
EP 2853898A1
· 2015
[cited by applicant]
EP 3922645
· 2021
[cited by applicant]
GB 2177096B
· 1989
[cited by applicant]
JP 2003520839
· 2003
[cited by applicant]
JP 2004504826
· 2004
[cited by applicant]
JP 2009545313
· 2009
[cited by applicant]
JP 2010502633
· 2010
[cited by applicant]
JP 2012520887
· 2012
[cited by applicant]
JP 2017536354
· 2017
[cited by applicant]
KR 20070105685A
· 2007
[cited by applicant]
WO WO9002809A1
· 1990
[cited by applicant]
WO WO9117271A1
· 1991
[cited by applicant]
WO WO9201047A1
· 1992
[cited by applicant]
WO WO9209690A2
· 1992
[cited by applicant]
WO WO9215679A1
· 1992
[cited by applicant]
WO WO9218619A1
· 1992
[cited by applicant]
WO WO9220791A1
· 1992
[cited by applicant]
WO WO9301288A1
· 1993
[cited by applicant]
WO WO1996001845A2
· 1996
[cited by applicant]
WO WO0053211A2
· 2000
[cited by applicant]
WO WO2002009641A2
· 2002
[cited by applicant]
WO WO2002085306A2
· 2002
[cited by applicant]
WO WO2003027248A2
· 2003
[cited by applicant]
WO WO2004009776A2
· 2004
[cited by applicant]
WO WO2004024890A2
· 2004
[cited by applicant]
WO WO2004037861A2
· 2004
[cited by applicant]
WO WO2005066204A2
· 2005
[cited by applicant]
WO WO2005084699A1
· 2005
[cited by applicant]
WO WO2005103081A2
· 2005
[cited by applicant]
WO WO2005115439A2
· 2005
[cited by applicant]
WO WO2006116269A2
· 2006
[cited by applicant]
WO WO2007024535A2
· 2007
[cited by applicant]
WO WO2007044411A3
· 2007
[cited by applicant]
WO WO2007047112A2
· 2007
[cited by applicant]
WO WO2007061995A2
· 2007
[cited by applicant]
WO WO2008030367A2
· 2008
[cited by applicant]
WO WO2008067480A2
· 2008
[cited by applicant]
WO WO2008119426A1
· 2008
[cited by applicant]
WO WO2009038760A2
· 2009
[cited by applicant]
WO WO2010070094A1
· 2010
[cited by applicant]
WO WO2010125003A1
· 2010
[cited by applicant]
WO WO2010144452A1
· 2010
[cited by applicant]
WO WO2011122011A2
· 2011
[cited by applicant]
WO WO2011150008A1
· 2011
[cited by applicant]
WO WO2012024242A1
· 2012
[cited by applicant]
WO WO2013071056A2
· 2013
[cited by applicant]
WO WO2013072902A1
· 2013
[cited by applicant]
WO WO2013074557A1
· 2013
[cited by applicant]
WO WO2013148284A1
· 2013
[cited by applicant]
WO WO2013165972A2
· 2013
[cited by applicant]
WO WO2013186719A1
· 2013
[cited by applicant]
WO WO2014074532A2
· 2014
[cited by applicant]
WO WO2014182676A2
· 2014
[cited by applicant]
WO WO2015070158A1
· 2015
[cited by applicant]
WO WO2015195094A1
· 2015
[cited by applicant]
WO WO2016073853A1
· 2016
[cited by applicant]
WO WO2016073879A2
· 2016
[cited by applicant]
WO WO2016073906A2
· 2016
[cited by applicant]
WO WO2016098357A1
· 2016
[cited by applicant]
WO WO2016168613A1
· 2016
[cited by applicant]
WO WO2017049011A1
· 2017
[cited by applicant]
WO WO2017104783A1
· 2017
[cited by applicant]
WO WO2017120523A2
· 2017
[cited by applicant]
WO WO2017218592A1
· 2017
[cited by applicant]
WO WO2018116201A1
· 2018
[cited by applicant]
WO WO2018129395A1
· 2018
[cited by applicant]
WO WO2019193204A1
· 2019
[cited by applicant]
WO WO2020160291A2
· 2020
[cited by applicant]
WO WO2022093724A1
· 2022
[cited by applicant]
WO WO2022164351A1
· 2022
[cited by applicant]
WO WO2022271867A1
· 2022
[cited by applicant]
WO WO2023215384A2
· 2023
[cited by applicant]
WO WO2024064842A1
· 2024
[cited by applicant]
WO WO2024138076A1
· 2024
[cited by applicant]
Knappik et al., “Recombinant Antibody Expression and Purification”, Chapter 203 (pp. 1929-1943) of The Protein Protocols Handbook, 2009.
[cited by examiner]
Amthor et al. “Lack of myostatin results in excessive muscle growth but impaired force generation,” Proc Natl Acad Sci U S A. Feb. 6, 2007;104(6):1835-40.
[cited by applicant]
Benjamini et al. (1991) Immunology: A Short Course, 2nd edition, p. 40 only.
[cited by applicant]
Deguise et al. (2017) “New insights into SMA pathogenesis: immune dysfunction and neuroinflammation,” Ann Clin Transl Neurol. 4(7):522-53.
[cited by applicant]
Jablonka et al. (2022) “Therapy development for spinal muscular atrophy: perspectives for muscular dystrophies and neurodegenerative disorders,” Neurol Res Pract. 4(7):522-530.
[cited by applicant]
Rindt et al. (2012) “Transgenic inactivation of murine myostatin does not decrease the severity of disease in a model of Spinal Muscular Atrophy,” Neuromuscul Disord. 22(3):277-85.
[cited by applicant]
Suh et al. (2020) “GDF11 promotes osteogenesis as opposed to MSTN, and follistatin, a MSTN/GDF11 inhibitor, increases muscle mass but weakens bone,” Proc Natl Acad Sci U S A. 3;117(9):4910-4920.
[cited by applicant]
Abdiche et al. “Antibodies Targeting Closely Adjacent or Minimally Overlapping Epitopes Can Displace One Another”, PLoS One. Jan. 6, 2017;12(1):e0169535.
[cited by applicant]
Abdiche et al. “High-throughput epitope binning assays on label-free array-based biosensors can yield exquisite epitope discrimination that facilitates the selection of monoclonal antibodies with functional activity”, P…
[cited by applicant]
Al-Zaidy et al., “Follistatin Gene Therapy Improves Ambulation in Becker Muscular Dystrophy”, J Neuromuscul Dis. 2015; 2(3):185-192.
[cited by applicant]
Anonymous, “History of Changes for Study: NCT03921528”, Jan. 13, 2020. URL:https://clinicaltrials.gov/ct2/history/NCT03921528?V_13=View#StudyPage Top (6 pgs.).
[cited by applicant]
Anonymous, “NCT05115110: A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Ambulat Spinal Muscular Atrophy”, Nov. 1, 2021 (Nov. 1, 2021), URL:https://clinicaltrials…
[cited by applicant]
Anonymous, “Scholar Rock Announces Positive Proof-of-Concept Data from TOPAZ Phase 2 Trial Interim Analysis of SRK-015 in Patients with Type 2 and Type 3 Spinal Muscular Atrophy” Business Wire, Oct. 27, 2020. (7pgs.).
[cited by applicant]
Barrett et al., “A Randomized Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of the Novel Myostatin Inhibitor Apitegromab (SRK-015): A Potential Treatment for Spinal Muscular Atrophy”, May 8, 2021 vol. 38, No…
[cited by applicant]
Bowerman et al., “UK SMA Research Consortium. Therapeutic strategies for spinal muscular atrophy: SMN and beyond”, Dis Model Mech. 2017; 10(8):943-954.
[cited by applicant]
Cambridge Mass et al., “Scholar Rock Announces Positive Interim Results from Phase 1 Trial of SRK-015 in Healthy Volunteers and Updates on Future Development Plans”, Feb. 19, 2019. (3pgs.).
[cited by applicant]
Castellana et al., “Resurrection of a clinical antibody: template proteogenomic de novo proteomic sequencing and reverse engineering of an anti-lymphotoxin-α antibody”, Proteomics. Feb. 2011;11(3):395-405.
[cited by applicant]
Chan et al., “Bone Geometry is Altered by Follistatin-Induced Muscle Growth in Young Adult Male Mice”, JBMR Plus, 2021, 5(4):e10477 (12 pgs.).
[cited by applicant]
Corey, “Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy”, Nature Neuroscience, vol. 20, Feb. 13, 2017, pp. 497-499.
[cited by applicant]
Crawford et al., “Apitegromab in Spinal Muscular Atrophy (SMA): An Analysis of Multiple Efficacy Endpoints in the TOPAZ Trial (P15-5.005)”, American Academy of Neurology (May 3, 2022), vol. 98, No. 18 Supp.
[cited by applicant]
Crawford et al., “Relationship of pharmacokinetics and pharmacodynamics to apitegromab efficacy in patients with later-onset spinal muscular atrophy (Types 2 and 3 SMA): Results from the TOPAZ study”, Abstracts/Journal …
[cited by applicant]
Extended European Search Report in EP23158609.0, mailed Aug. 8, 2023, 27 pages.
[cited by applicant]
Gorgey et al., “Effects of spinal cord injury on body composition and metabolic profile—Part I” J Spinal Cord Med. 2014; 37(6):693-702.
[cited by applicant]
Hagan, “When are mice considered old?”, 2017, https://www.iax.org/news-and insights/jax-blog/2017/november/when-are-mice-considered-old.
[cited by applicant]
Hua et al., “Enhancement of SMN2 Exon 7 inclusion by Antisense Oligonucleotides Targeting the Exon”, PLOS Biology, Published Apr. 2007, vol. 5, pp. 0729-0742.
[cited by applicant]
International Search Report and Written Opinion of the International Searching Authority received in PCT/US2021/056517, mailed Mar. 2, 2022 (23 pgs.).
[cited by applicant]
International Search Report and Written Opinion of the International Searching Authority received in PCT/US2022/034588, mailed Jun. 10, 2022 (10 pgs.).
[cited by applicant]
International Search Report and Written Opinion of the International Searching Authority received in PCT/US2023/020843, mailed Oct. 30, 2023 (21 pgs.).
[cited by applicant]
Kubo et al., “A new method for SMN1 and hybrid SMN gene analysis in spinal muscular atrophy using long-range PCR followed by Sequencing”, Journal of Human Genetics, Published Feb. 26, 2015, pp. 233-238.
[cited by applicant]
Lee, “Myostatin: A Skeletal Muscle Chalone”, Annu Rev Physiol., 2023, 10;85:269-291.
[cited by applicant]
Markovits et al., The diversity of the immune response to the A2 domain of human factor VIII. Blood. Apr. 4, 2013;121(14):2785-95.
[cited by applicant]
Opposition Proceedings in EP 3368069—Carpmaels submission, Feb. 9, 2024 (127 pgs.).
[cited by applicant]
Opposition Proceedings in EP 3368069—Declaration of Ms. Ying Qian filed Feb. 9, 2024 (2pgs).
[cited by applicant]
Opposition Proceedings in EP 3368069—DFMP submission pursuant to Rule 116 EPC, Feb. 9, 2024 (13 pgs.).
[cited by applicant]
Opposition Proceedings in EP 3368069—Hoffmann Eitle comments under Rule 116 EPC, Feb. 9, 2024 (23 pgs.).
[cited by applicant]
Opposition Proceedings in EP 3368069—Hoffmann Eitle Submission, Apr. 2, 2024 (23 pgs.).
[cited by applicant]
Opposition Proceedings in EP 3368069—Second Declaration of Dr. Karen Chen (3 pgs.).
[cited by applicant]
Passey et al., “Emerging therapies for the treatment of skeletal muscle wasting in chronic obstructive pulmonary disease”, Pharmacol Ther. 2016; 166:56-70.
[cited by applicant]
Place et al., “A Phase 2 Study to Evaluate the Efficacy and Safety of SRK-015 in Patients with Later-Onset Spinal Muscular Atrophy (TOPAZ): An Introduction” May 26, 2020. URL:https://scholarrock.com/wp-content/uploads/2…
[cited by applicant]
Place et al., “SMA—THERAPY P.253 Clinical Development of SRK-015, a Fully Human Anti-proMyostatin Monoclonal Antibody, for the Treatment of Later-Onset Spinal Muscular Atrophy,” Abstracts/Neuromuscular Disorders, Elsevi…
[cited by applicant]
Place et al., “TOPAZ: Phase 2 study evaluating efficacy and safety of apitegromab in later-onset spinal muscular atrophy”, EMBASE2021, Database accession No. EMB-635747941, Retrieved from the Internet: URL:Elsevier Scie…
[cited by applicant]
Pyatt et al., “A feasability study for the newborn screening of spinal muscular atrophy”, Genetics in Medicine, Published Jul. 2006, vol. 8, pp. 428-435.
[cited by applicant]
Saitoh et al., “Myostatin inhibitors as pharmacological treatment for muscle wasting and muscular dystrophy”, Journal of Cachexia, Sarcopenia and Muscle - Clinical Reports, vol. 2, Issue 1, 2017, e00037 (10 pgs.).
[cited by applicant]
Scholar Rock press release (2021): Scholar Rock Announces Positive 12-Month Top-Line Results From the TOPAZ Phase 2 Clinical Trial Evaluating Apitegromab in Patients With Type 2 and Type 3 Spinal Muscular Atrophy (SMA).
[cited by applicant]
Scholar Rock stuns with positive results for SRK-015 in SMA patients (2020) (https://www.thepharmaletter.com/article/scholar-rock-stuns-with-positive- resultsfor-srk-015-in-smapatients#>:text=US%20clinical%2Dstage%20bio…
[cited by applicant]
Second Written Opinion of the International Preliminary Examining Authority for PCT/US2017/012606 dated Jan. 3, 2018.
[cited by applicant]
Sidis et al., “Biological activity of follistatin isoforms and follistatin-like-3 is dependent on differential cell surface binding and specificity for activin, myostatin, and bone morphogenetic proteins”, Endocrinology…
[cited by applicant]
Staels et al., “Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease”, Nat Clin Pract Cardiovasc Med. 2008, 5(9):542-53.
[cited by applicant]
Trevogrumab: Statement on a Nonproprietary Name Adopted By the Usan Council (2015) (https://searchusan.amaassn.org/undefined/documentDownload?uri=%2Funstructured%2Fbinary%2Fusan%2Ftrevogrumab.pdf).
[cited by applicant]
U.S. Appl. No. 62/486,934, filed Apr. 18, 2017.
[cited by applicant]
Vai et al., “Bone and Spinal Muscular Atrophy”, Bone. 2015; 79:116-20.
[cited by applicant]
Wallner et al., “Inhibition of GDF8 (Myostatin) accelerates bone regeneration in diabetes mellitus type 2”, Sci Rep. Aug. 29, 2017;7(1):9878 (11 pgs.).
[cited by applicant]
Zhou et al., “Myostatin inhibition in combination with antisense oligonucleotide therapy improves outcomes in spinal muscular atrophy”, J Cachexia Sarcopenia Muscle. 2020, 11(3):768-782.
[cited by applicant]
Anderson et al., (2008) “Identification of a novel pool of extracellular pro myostatin in skeletal muscle”, The Journal of Biological Chemistry, 283(11):7027-7035.
[cited by applicant]
Anonymous (2005) “Human Myostatin ELISA—Prodomain specific”, BioVendor Laboratory Medicine, Inc., XP055100354, Retrieved from the Internet: URL:http://deltaclon.es/pdf/RD193058100.pdf (10 pgs.).
[cited by applicant]
Anonymous (2017) “SC 2. Anterolateral Systems—Deficits” [online]. Retrieved from: http://www.neuroanatomy.wisc.edu/sc97/text/p2/deficits.htm; on Jul. 11, 2017 (1 page).
[cited by applicant]
Anonymous (2019) “GDF-11/BMP-11 Mouse anti-Human, Clone: 743833, R&D Systems(TM)” [online]. Retrieved from: http://www.fishersci.co.uk/shop/products/gdf-11bpm-11-mouse-anti-human-clone-743833-r-d-systems/15724724; on Fe…
[cited by applicant]
Australian Application No. 202010134, filed Jul. 27, 2020, for Scholar Rock, Inc.: Examination Report No. 1, issued Oct. 15, 2020.
[cited by applicant]
Baranello et al., (2020) “Evaluation of body composition as a potential biomarker in spinal muscular atrophy”, Muscle & Nerve, 61(4):530-534.
[cited by applicant]
Benatar (2007) “Lost in translation: Treatment trials in the SOD1 mouse and in human ALS”, Neurobiology of Disease, 26:1-13.
[cited by applicant]
Bernardo et al. (2010) “Postnatal PPARdelta activation and myostatin inhibition exert distinct yet complimentary effects on the metabolic profile of obese insulin-resistant mice,” PLoS One. 25;5(6):e11307.
[cited by applicant]
Biovendor, Research and Diagnostics Products. Myostatin Propeptide Human, Chicken Polyclonal Antibody. Product Data Sheet 2 pgs. Apr. 11, 2013.
[cited by applicant]
Bräuninger et al., (2003) “Epstein-Barr virus (EBV)-positive lymphoproliferations in post-transplant patients show immunoglobulin V gene mutation patterns suggesting interference of EBV with normal B cell differentiatio…
[cited by applicant]
Breitbart et al., (2013) “Highly specific detection of myostatin prodomain by an immunoradiometric sandwich assay in serum of healthy individuals and patients”, PLoS One, 8(11):e80454 (10 pgs.).
[cited by applicant]
Brown et al., (1996) “Tolerance of single, but not multiple, amino acid replacements in antibody VH CDR 2: a means of minimizing B cell wastage from somatic hypermutation?”, J Immunol., 156(9):3285-3291.
[cited by applicant]
Burch et al., (2017) “Reduced serum myostatin concentrations associated with genetic muscle disease progression”, Journal of Neurology, 264(3):541-553.
[cited by applicant]
Chen Declaration filed in opposition of EP Patent No. 3368069 on Apr. 27, 2022 ( 2pgs.).
[cited by applicant]
Chen et al., “Considerations for Developing Combination Therapies in SMA”, Cure SMA Researcher Meeting, Jun. 16, 2016.
[cited by applicant]
Ciciliot et al., (2013) “Muscle type and fiber type specificity in muscle wasting”, Int J Biochem Cell Biol., 45(10):2191-2199.
[cited by applicant]
Cohen et al., (2015) “Muscle wasting in disease: molecular mechanisms and promising therapies”, Nat Rev Drug Discov., 14(1):58-74.
[cited by applicant]
Cully, (2014) “Beefing up the right splice variant to treat spinal muscular atrophy”.
[cited by applicant]
Cure SMA Presentation filed in opposition of EP Patent No. 3368069 on Apr. 27, 2022 (86 pgs.).
[cited by applicant]
Dagbay et al., (2020) “Structural basis of specific inhibition of extracellular activation of pro- or latent myostatin by the monoclonal antibody SRK-015”, J. Biol. Chem., 295(16):5404-5418.
[cited by applicant]
Dalbo et al., (2017) “Testosterone and trenbolone enanthate increase mature myostatin protein expression despite increasing skeletal muscle hypertrophy and satellite cell number in rodent muscle”, Andrologia, 49(3):1-11.
[cited by applicant]
Day et al., (2021) “Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial”, Lan…
[cited by applicant]
Dibernardo et al., (2006) “Translating preclinical insights into effective human trials in ALS”, Biochimica et Biophysica Acta, 1762:1139-1149.
[cited by applicant]
D'ydewalle et al., (2015) “Spinal muscular atrophy therapeutics: where do we stand?”, Neurotherapeutics, 12(2):303-316.
[cited by applicant]
Egerman et al., (2015) “GDF11 Increases with Age and Inhibits Skeletal Muscle Regeneration”, Cell Metabolism, 22(1):164-174.
[cited by applicant]
European Patent Application No. 16828657.3, by Scholar Rock, Inc.: Supplementary European Search Report and Opinion, dated Mar. 20, 2019.
[cited by applicant]
European Patent Application No. 20179533.3, by Scholar Rock, Inc.: Partial European Search Report, dated Mar. 31, 2021 (12 pgs.).
[cited by applicant]
European Patent Application No. 20193425.4, by Scholar Rock, Inc.: European Search Report, dated Apr. 1, 2021 (9 pgs.).
[cited by applicant]
Extended European Search Report in EP Application No. 21170667.6 dated Nov. 11, 2021.
[cited by applicant]
Farrar et al. (2017) “Emerging therapies and challenges in spinal muscular atrophy” Ann Neural 81(3): 355-368. Published online Feb. 1, 20177. doi: 10.1002/ana.24864. Publication details included.
[cited by applicant]
Feng et al., (2016) “Pharmacologically induced mouse model of adult spinal muscular atrophy to evaluate effectiveness of therapeutics after disease onset”, Human Molecular Genetics, 25(5):964-975.
[cited by applicant]
Ferrara et al., (2015) “Recombinant renewable polyclonal antibodies”, MAbs, 7(1):32-41.
[cited by applicant]
Fidler, (2016) “Scholar Rock Rolls Up $36M to Move Muscle Drug to Clinical Trials” https://xconomy.com/boston/2016/01/04/scholar-rock-rolls-up-36m-to-move-muscle-drug-to-clinical-trials/.
[cited by applicant]
Ge et al., (2005) “GDF11 Forms a Bone Morphogenetic Protein 1-Activated Latent Complex That Can Modulate Nerve Growth Factor—Induced Differentiation of PC12 Cells”, Molecular and Cellular Biology, 25(14):5846-5858.
[cited by applicant]
Giangregorio et al., (2006) “Bone Loss and Muscle Atrophy in Spinal Cord Injury: Epidemiology, Fracture Prediction, and Rehabilitation Strategies”, J Spinal Cord Med., 29(5):489-500.
[cited by applicant]
Gogliotti et al., (2011) “Characterization of a commonly used mouse model of SMA reveals increased seizures susceptibility and heightened fear response in FVB/N mice”, Neurobiol Dis. 43(1):142-151.
[cited by applicant]
Gonzalez et al., (2005) “BMP-1/Tolloid-like Metalloproteases Process Endorepellin, the Angiostatic C-terminal Fragment of Perlecan”, The Journal of Biological Chemistry, 280(8):7080-7087.
[cited by applicant]
Graham et al., (2015) “A Soluble Myostatin Inhibitor Does Not Prevent Sublesional Muscle Atrophy 56 Days After Spinal Cord Injury in Mice”, Medicine & Science in Sports & Exercise, Abstract No. 2219:587.
[cited by applicant]
Guo et al., (2009) “Myostatin Inhibition in Muscle, but Not Adippose Tissue, Decreases Fat Mass and Improves Insulin Sensitivity”, PLoS One, 4(3):e4937 (11 pgs.).
[cited by applicant]
Heymsfield et al., (2021) “Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity: A Phase 2 Randomized Clinical Trial”, 4(1):e2033457. doi: 10.1001/jamanetworkopen.2020.33457.
[cited by applicant]
Holzbaur et al., (2006) “Myostatin inhibition slows muscle atrophy in rodent models of amyotrophic lateral sclerosis”, Neurobiol Dis., 23(3):697-707.
[cited by applicant]
Hori et al. (2022) “Elimination of plasma soluble antigen in cynomolgus monkeys by combining pH-dependent antigen binding and novel Fc engineering” MAbs. 14(1):2068213. doi: 10.1080/19420862.2022.2068213.
[cited by applicant]
Igawa et al. (2013) “Engineered Monoclonal Antibody with Novel AntigenSweeping Activity In Vivo”. PLoS One 8(5):e63236.
[cited by applicant]
Iinternational Search Report for Application No. PCT/US2015/059557, dated May 19, 2016 (5 pgs.).
[cited by applicant]
International Application No. PCT/US2016/043712, by Scholar Rock, Inc., International Search Report and Written Opinion, mailed Jan. 13, 2017.
[cited by applicant]
International Application No. PCT/US2017/012606, by Scholar Rock, Inc., International Search Report and Written Opinion, mailed Jul. 24, 2017.
[cited by applicant]
International Application No. PCT/US2017/012606, by Scholar Rock, Inc., Written Opinion mailed Jan. 3, 2018 (18 pgs.).
[cited by applicant]
International Application No. PCT/US2017/037332, by Scholar Rock, Inc., International Search Report and Written Opinion, mailed Nov. 14, 2017.
[cited by applicant]
International Application No. PCT/US2018/012686, by Scholar Rock, Inc., International Search Report and Written Opinion, mailed Apr. 3, 2018.
[cited by applicant]
International Preliminary Report on Patentability for Application No. PCT/US2015/059468, dated May 9, 2017 (12 pgs.).
[cited by applicant]
International Preliminary Report on Patentability for Application No. PCT/US2015/059515, dated May 9, 2017 (12 pgs.).
[cited by applicant]
International Preliminary Report on Patentability for Application No. PCT/US2015/059557, dated May 9, 2017 (12 pgs.).
[cited by applicant]
International Preliminary Report on Patentability for Application No. PCT/US2016/052014, dated Mar. 29, 2018 (11 pgs.).
[cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2016/052014, dated Jan. 9, 2017 (17 pgs.).
[cited by applicant]
International Search Report for Application No. PCT/US2015/059468, dated Apr. 4, 2016 (6 pgs.).
[cited by applicant]
International Search Report for Application No. PCT/US2015/059515, dated Mar. 25, 2016 (8 pgs.).
[cited by applicant]
Japanese Patent Application No. 2019-517209, filed Jun. 13, 2017, by Scholar Rock, Inc., Decision to Grant a Patent, mailed Dec. 8, 2020 (7 pgs.).
[cited by applicant]
Jarecki Declaration filed in opposition of EP Patent No. 3368069 on Apr. 27, 2022 (2 pgs.).
[cited by applicant]
Jarolim et al., (2013) “2013 AACC Annual Meeting Abstracts B-175 Determination of Cardiac Troponin with a Single-Molecule High-Sensitivity Assay and Outcomes in Patients with Stable Coronary Artery Disease: Analysis fro…
[cited by applicant]
Jiang et al., (2019) “Genomic analysis of a spinal muscular atrophy (SMA) discordant family identifies a novel mutation in TLL2, an activator of growth differentiation factor 8 (myostatin): a case report”, BMC Medical G…
[cited by applicant]
Jobling et al. (2006) “Isoform-specific activation of latent transforming growth factor beta (LTGF-beta) by reactive oxygen species”, Radiat Res. 166(6):839-48.
[cited by applicant]
Kariya et al., (2014) “Requirement of enhanced Survival Motoneuron protein imposed during neuromuscular junction maturation”, The Journal of Clinical Investigation, 124(2):785-800.
[cited by applicant]
Latres et al., (2015) “Myostatin blockade with a fully human monoclonal antibody induces muscle hypertrophy and reverses muscle atrophy in young and aged mice”, Skeletal Muscle, 5:34.
[cited by applicant]
Latres et al., (2017) “Activin A more prominently regulates muscle mass in primates than does GDF8”, Nature Communications, 8:15153.
[cited by applicant]
Ling et al. (2012) “Severe neuromuscular denervation of clinically relevant muscles in a mouse model of spinal muscular atrophy” Human Molecular Genetics, vol. 21, No. 1, pp. 185-195.
[cited by applicant]
Liu et al., (2014) “The Smn-Independent Beneficial Effect of Trichostatin A on an Intermediate Mouse Model of Spinal Muscular Atrophy”, Plos One, 9(7):e101225.(9 pgs.).
[cited by applicant]
Liu et al., (2016) Activin Receptor Type 118 Inhibition Improves Muscle Phenotype and Function in a Mouse Model of Spinal Muscular Atrophy, PLoS One 11 (11): e0166803, published Nov. 21, 2016.
[cited by applicant]
Loffredo et al., (2013) “Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy”, Cell, 153(4):828-839.
[cited by applicant]
Long et al., (2019) “Specific inhibition of myostatin activation is beneficial in mouse models of SMA therapy”, Human Molecular Genetics, 28(7):1076-1089.
[cited by applicant]
Mariot et al., (2017) “Downregulation of myostatin pathway in neuromuscular diseases may explain challenges of anti-myostatin therapeutic approaches”, Nature Communications, 8(1):1859.
[cited by applicant]
McPherron et al., (2010) “Metabolic Functions of Myostatin and GDF11”, Immunol Endocr Metab Agents Med Chem., 10(4):217-231.
[cited by applicant]
Morrison et al., (2009) “A soluble activin type IIB receptor improves function in a mouse model of amyotrophic lateral sclerosis”, Exp Neurol, 217(2):258-268.
[cited by applicant]
Mosler et al., (2012) “The anabolic steroid methandienone targets the hypothalamic-pituitary-testicular axis and myostatin signaling in a rat training model”, Archives of Toxicology, 86(1):109-119.
[cited by applicant]
Muramatsu et al., (2021) “Novel myostatin-specific antibody enhances muscle strength in muscle disease models” , Sci Rep, 11:2160, https://doi.org/10.1038/s41598-021-81669-8 (16 pgs.).
[cited by applicant]
Naryshkin et al., (2014) “SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy” Science, vol. 345, Issue 6197, pp. 688-693, DOI: 10.1126/science.1250127.
[cited by applicant]
Ojala et al., (2021) “In Search of a Cure: The Development of Therapeutics to Alter the Progression of Spinal Muscular Atrophy”, Brain Sci., 11:194 (39 pgs.).
[cited by applicant]
Opposition filed in EP Patent No. 3368069 on Apr. 28, 2021 (37 pgs.).
[cited by applicant]
Opposition filed in EP Patent No. 3368069 on May 4, 2021 (89 pgs.).
[cited by applicant]
Opposition Pre-summons Response filed in EP Patent No. 3368069 on Apr. 27, 2022 (33 pgs.).
[cited by applicant]
Pandya et al., (2013) “Therapeutic neuroprotective agents for amyotrophic lateral sclerosis”, Cell Mol Life Sci., 70(24):4729-4745.
[cited by applicant]
Pirruccello-Straub et al., (2018) “Blocking extracellular activation of myostatin as a strategy for treating muscle wasting”, Scientific Reports, 8(1):2292.
[cited by applicant]
Pistilli et al., (2011) “Targeting Activin Type IIB Receptor to Improve Muscle Mass and Function in the mdx Mouse Model of Duchenne Muscular Dystrophy”, Am J Pathol., 178(3):1287-1297.
[cited by applicant]
Pubchem Substance No. CID 310264710 (trevogrumab); Create Date Feb. 5, 2016 [online]. Retrieved from: http://pubchem.ncbi.nlm.nih.gov/substance/310264710; on Feb. 5, 2020 (6 pgs.).
[cited by applicant]
Reply to Examination Report dated Feb. 13, 2016 in EP Application No. 17732001.7, on May 31, 2019.
[cited by applicant]
Request for early entry and processing of EP Application No. 17732001.7, on Jun. 1, 2018.
[cited by applicant]
Response to Communication dated Jul. 31, 2018 in EP Application No. 17732001.7, on Dec. 10, 2018.
[cited by applicant]
Rodino-Klapac et al., (2009) “Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease” Muscle Nerve 39(3):283-96. doi: 10.1002/mus.21244.
[cited by applicant]
Rose et al., (2009) “Delivery of recombinant follistatin lessens disease severity in a mouse model of spinal muscular atrophy” Hum Mol Genet. Mar. 15, 2009; 18(6): 997-1005, Published online Dec. 12, 2008. doi: 10.1093/…
[cited by applicant]
Roth et al., (2004) “Myostatin: a therapeutic target for skeletal muscle wasting” Curr Opin Clin Nutr Metab Care 7(3):259-63. doi: 10.1097/00075197-200405000-00004.
[cited by applicant]
Schoch et al., (2015) “Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics”, Proceedings of the National Academy of Sciences, vol. 112, No. 19, pp. 5997-6002.
[cited by applicant]
ScholarRock Announcement (2015) “Scholar Rock Presents First Data for Niche Modulator Inhibiting Myostatin Activation and Announces SRK-015 as Lead Drug Program” (1 pg.).
[cited by applicant]
ScholarRock.com (2016) “Scholar Rock discovered SRK-015, a selective and local inhibitor or latent myostatin activation for the treatment of primary myopathies” (1 pg.).
[cited by applicant]
Sgoutas et al., (1992) “Effect of Lyophilization on Determinations of Lipoprotein(a) in Serum”, Clin Chem., 38(7):1355-1360.
[cited by applicant]
Shorrock et al., (2016) “Development and Translation of Therapies for Spinal Muscular Atrophy” EMJ Neurol. 4[1]:64-73.
[cited by applicant]
Singapore Patent Application No. 11201805709R, filed Jan. 6, 2017, by Scholar Rock, Inc.: International Search Report and Written Opinion, mailed Oct. 11, 2019 (12 pgs.).
[cited by applicant]
SMA Annual Conference “The 2016 Annual SMA Conference is here”, https://www.curesma.org/the-2016-annual-sma-conference-is-here/ (3 pgs.).
[cited by applicant]
SMA Researcher Meeting Summary: The Changing Landscape of SMA 2016 (5 pgs.).
[cited by applicant]
Smith et al., (2013) “Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders”, Curr Opin Support Palliat Care, 7(4):352-360.
[cited by applicant]
Smith et al., (2015) “Myostatin Neutralization Results in Preservation of Muscle Mass and Strength in Preclinical Models of Tumor-Induced Muscle Wasting”, Mol Cancer Ther., 14(7):1661-1670.
[cited by applicant]
Spinraza (Nusinersen) FDA label, Dec. 2016 (13 pgs.).
[cited by applicant]
Sumner et al. (2016) “Spinal Muscular Atrophy, Disease Mechanisms and Therapy”, Academic Press, pp. 6, 15-19 and 351-356. Publication details included (22 pgs).
[cited by applicant]
Sumner et al., (2009) “Inhibition of myostatin does not ameliorate disease features of severe spinal muscular atrophy mice”, Human Molecular Genetics, 18(17):3145-3152.
[cited by applicant]
Sumner et al., (2016) “Spinal Muscular Atrophy, Disease Mechanisms and Therapy”, First edition, Academic Press, Chapters 15, 16, 21, and 23. Publication details included (91 pgs.).
[cited by applicant]
Suragani et al., (2014) “Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis”, Nature Medicine, 20(4):408-414.
[cited by applicant]
Szlama et al., (2013) “Latent myostatin has significant activity and this activity is controlled more efficiently by WFIKKN1 than by WFIKKN2”, FEBS Journal, 280(16):3822-3839.
[cited by applicant]
Unknown (2000) American Spinal Injury Association (ASIA) Impairment Scale, Standard Neurological Classification of Spinal Cord Injury (2 pgs.).
[cited by applicant]
Unknown (2013) “Myostatin Propeptide Human, Chicken Polyclonal Antibody”, BioVendor, Research and Diagnostic Products, Data Sheet (2 pgs.).
[cited by applicant]
Wagner, (2020) “The elusive promise of myostatin inhibition for muscular dystrophy”, Current Opinion in Neurology, 33(5):621-628.
[cited by applicant]
Walker et al., Biochemistry and Biology of GDF11 and Myostatin: similarities, differences and questions for future investigation, Cir. Res. 118(7): 1125-1142, published Apr. 1, 2016.
[cited by applicant]
Walter et al., (2021) “Improving Care and Empowering Adults Living with SMA: A Call to Action in the New Treatment Era”, Journal of Neuromuscular Diseases, DOI 10.3233/JND-200611 (9 pgs.).
[cited by applicant]
Wang (2000) “Lyophilization and development of solid protein pharmaceuticals”, International Journal of Pharmaceutics, 203(1-2):1-60.
[cited by applicant]
Whittemore et al., (2003) “Inhibition of myostatin in adult mice increases skeletal muscle mass and strength”, Biochem Biophys Res Commun, 300(4):965-971.
[cited by applicant]
Wintgens et al., (2012) “Plasma myostatin measured by a competitive ELISA using a highly specific antiserum”, Clin Chim Acta., 413(15-16):1288-1294.
[cited by applicant]
Wolfman et al., (2003) “Activation of latent myostatin by the BMP-1/tolloid family of metalloproteinases”, Proc Natl Acad Sci U.S.A., 100(26):15842-15846.
[cited by applicant]
Zhao et al., (2016) “Pharmacokinetics, pharmacodynamics, and efficacy of a small molecule SMN2 splicing modifier in mouse models of spinal muscular atrophy”, Human Molecular Genetics, 25(10):1885-1899.
[cited by applicant]
Bailey. “GIP analogues and the treatment of obesity-diabetes,” Peptides. Mar. 2020;125:170202.
[cited by applicant]
Bhattacharya et al. “Application of quantitative pharmacology approaches in bridging pharmacokinetics and pharmacodynamics of domagrozumab from adult healthy subjects to pediatric patients with Duchenne muscular disease…
[cited by applicant]
Fock et al., “Diet and exercise in management of obesity and overweight,” J Gastroenterol Hepatol. Dec. 2013; 28 Suppl 4:59-63.
[cited by applicant]
Foster “Malonyl-CoA: the regulator of fatty acid synthesis and oxidation”, J Clin Invest. 2012;122(6):1958-1959.
[cited by applicant]
Golan et al. “LY2495655, an antimyostatin antibody, in pancreatic cancer: a randomized, phase 2 trial”, Journal of Cachexia, Sarcopenia and Muscle. 2018;9(5):871-879.
[cited by applicant]
Gonzalez Trotter et al. “34-OR: The Effect of Combined Activin A and Myostatin Blockade on Body Composition—A Phase 1 Trial. Diabetes”, 2024;73(Supplement_1).
[cited by applicant]
Hamrick. “The skeletal muscle secretome: an emerging player in muscle-bone crosstalk”, Bonekey Rep. Apr. 11, 2012;1:60. (5 pgs.).
[cited by applicant]
Hansen et al., “Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes—a review,” Diabetes Metab Syndr Obes. May 17, 2010;3:155-63.
[cited by applicant]
Incretin mimetic drugs for type 2 diabetes—FDA, downloaded on Sep. 9, 2024 (1 pg.).
[cited by applicant]
International Search Report and Written Opinion of the International Searching Authority received in PCT/US2023/085574, mailed May 7, 2024 (16 pgs.).
[cited by applicant]
Kaufmann et al. “Observational study of spinal muscular atrophy type 2 and 3: functional outcomes over 1 year,” Arch Neurol. Jun. 2011;68(6):779-86.
[cited by applicant]
List of Incretin Mimetics (GLP-1 Agonists) (GLP-1 Analogues)—Drugs.com, downloaded Sep. 9, 2024.
[cited by applicant]
Liu et al., “New practice in semaglutide on type-2 diabetes and obesity: clinical evidence and expectation”, Frontiers of Medicine, Higher Education Press, Heidelberg, vol. 16, No. 1, Feb. 1, 2022, 17-24.
[cited by applicant]
Miller et al. “The danger of weight loss in the elderly”, J Nutr Health Aging. Aug.-Sep. 2008;12(7):487-91.
[cited by applicant]
Muramatsu et al., “Novel myostatin-specific antibody enhances muscle strength in muscle disease models”, Scientific Reports, vol. 11, No. 1, Jan. 25, 2021.
[cited by applicant]
Nguyen, “Oral-033: Bimagrumab + Semaglutide Causes> 30% Fat Loss and 5% Lean Mass Increase in Obese Mice After 2 Weeks”, Obesity, vol. 30, No. SI, Nov. 1, 2022, 4-54.
[cited by applicant]
Oestreich et al. “Myostatin deficiency partially rescues the bone phenotype of osteogenesis imperfecta model mice”, Osteoporos Int. Jan. 2016;27(1):161-70.
[cited by applicant]
Opposition Proceedings in EP 3368069 Brief Communication from EPO Oct. 10, 2024(63 pgs.).
[cited by applicant]
Singh et al.“Translational pharmacokinetic/pharmacodynamic analysis of myo-029 antibody for muscular dystrophy”, Clinical and Translational Science. 2016;9(6):302-310.
[cited by applicant]
Tang et al. “Inhibiting myostatin signaling prevents femoral trabecular bone loss and microarchitecture deterioration in diet-induced obese rats”, Exp Biol Med (Maywood). Feb. 2016;241(3):308-16.
[cited by applicant]
Tao et al. “Genetic Inactivation of Pyruvate Dehydrogenase Kinases Improves Hepatic Insulin Resistance Induced Diabetes”, Plos One. 2013, 8(8):1-8.
[cited by applicant]
Wagner et al. “A phase I/II trial of MYO-029 in adult subjects with muscular dystrophy”, Annals of Neurology. 2008;63(5):561-571.
[cited by applicant]
Wagner et al. “Randomized phase 2 trial and open-label extension of domagrozumab in Duchenne muscular dystrophy”, Neuromuscular Disorders. 2020;30(6):492-502.
[cited by applicant]
Woodhouse et al. “A Phase 2 Randomized Study Investigating the Efficacy and Safety of Myostatin Antibody LY2495655 versus Placebo in Patients Undergoing Elective Total Hip Arthroplasty”, The Journal of Frailty & Aging. …
[cited by applicant]
Yumuk et al. “European Guidelines for Obesity Management in Adults”, Obes Facts Dec. 1, 2015; 8 (6):402-424.
[cited by applicant]
Adams et al., “Comparison of the effects of body-weight-supported treadmill training and tilt-table standing on spasticity in individuals with chronic spinal cord injury,” J Spinal Cord Med. 2011;34(5):488-94.
[cited by applicant]
Ader, D., “Developing the patient-reported outcomes measurement information system (PROMIS),” Medical care 45.5 (2007): S1-S2.
[cited by applicant]
Alfano et al., “Validity and reliability of the neuromuscular gross motor outcome,” Pediatric Neurology 122 (2021): 21-26.
[cited by applicant]
Altschul et al., “Basic local alignment search tool,” Journal of molecular biology 215.3 (1990): 403-410.
[cited by applicant]
Altschul et al., “Gapped BLAST and PSI-BLAST: a new generation of protein database search programs,” Nucleic acids research 25.17 (1997): 3389-3402.
[cited by applicant]
Alves et al., “Serum creatinine is a biomarker of progressive denervation in spinal muscular atrophy,” Neurology 94.9 (2020): e921-e931.
[cited by applicant]
Amato et al., “Treatment of sporadic inclusion body myositis with bimagrumab,” Neurology 83.24 (2014): 2239-2246.
[cited by applicant]
Ambery et al., “MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study,” The Lancet 391.1014…
[cited by applicant]
Angal et al., “A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (lgG4) antibody,” Molecular immunology 30.1 (1993): 105-108.
[cited by applicant]
Annoussamy et al., “Natural history of Type 2 and 3 spinal muscular atrophy: 2-year NatHis-SMA study,” Annals of Clinical and Translational Neurology 8.2 (2021): 359-373.
[cited by applicant]
Applebaum et al., “Modified 30-second Sit to Stand test predicts falls in a cohort of institutionalized older veterans,” Plos one 12.5 (2017): 1-13.
[cited by applicant]
Aragon-Gawinska et al., “Nusinersen in patients older than 7 months with spinal muscular atrophy type 1: a cohort study,” Neurology 91.14 (2018): e1312-e1318.
[cited by applicant]
Aronne et al., “Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial,” Jama, 331.1, (2024): 38-48.
[cited by applicant]
Awano et al., “Spinal muscular atrophy: journeying from bench to bedside,” Neurotherapeutics 11.4 (2014): 786-795.
[cited by applicant]
Axente et al., “Clinical features and genetics in non-5q spinal muscular atrophy caused by acid ceramidase deficiency,” Journal of Medicine and Life 14.3 (2021): 1-5.
[cited by applicant]
Bahne et al., “Metformin-induced glucagon-like peptide-1 secretion contributes to the actions of metformin in type 2 diabetes,” JCI insight, 3.23, (2018): 1-16.
[cited by applicant]
Baranello et al., “Risdiplam in type 1 spinal muscular atrophy,” New England Journal of Medicine 384.10 (2021): 915-923.
[cited by applicant]
Bartels et al., “Fatigability in spinal muscular atrophy: validity and reliability of endurance shuttle tests,” Orphanet Journal of Rare Diseases 15 (2020): 1-9.
[cited by applicant]
Battaglino et al., “Spinal cord injury-induced osteoporosis: pathogenesis and emerging therapies,” Curr Osteoporos Rep. Dec. 2012; 10(4):278-85.
[cited by applicant]
Becker et al., “Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial,” The Lancet Diabetes & Endocrinology. 2015;3(12):948-957.
[cited by applicant]
Belhayara et al., “The metabolic syndrome: emerging novel insights regarding the relationship between the homeostasis model assessment of insulin resistance and other key predictive markers in young adults of Western Al…
[cited by applicant]
Bergen et al., “Myostatin as a mediator of sarcopenia versus homeostatic regulator of muscle mass: insights using a new mass spectrometry-based assay,” Skeletal muscle 5 (2015): 1-16.
[cited by applicant]
Bhattacharya et al., “Comparative analysis of silencing expression of myostatin (MSTN) and its two receptors (ACVR2A and ACVR2B) genes affecting growth traits in knock down chicken,” Scientific reports 9.1 (2019): 1-13.
[cited by applicant]
Bird et al., “Single-chain antigen-binding proteins,” Science 242.4877 (1988): 423-426.
[cited by applicant]
Bolon et al., “STP position paper: recommended best practices for sampling, processing, and analysis of the peripheral nervous system (nerves and somatic and autonomic ganglia) during nonclinical toxicity studies,” Toxi…
[cited by applicant]
Bolon et al., “STP position paper: recommended practices for sampling and processing the nervous system (brain, spinal cord, nerve, and eye) during nonclinical general toxicity studies,” Toxicologic pathology 41.7 (2013…
[cited by applicant]
Brakemeier et al., “Assessment of bulbar function in adult patients with 5q-SMA type 2 and 3 under treatment with nusinersen,” Brain Sciences 11.9 (2021): 1-9.
[cited by applicant]
Butler et al., “Reversing type 1 diabetes with stem cell-derived islets: a step closer to the dream?” The Journal of Clinical Investigation 132.3 (2022): 1-2.
[cited by applicant]
Cabri et al., “Therapeutic peptides targeting PPI in clinical development: Overview, mechanism of action and perspectives,” Frontiers in Molecular Biosciences 8 (2021): 1-21.
[cited by applicant]
Calder et al., “Small molecules in development for the treatment of spinal muscular atrophy: miniperspective,” Journal of medicinal chemistry 59.22 (2016): 10067-10083.
[cited by applicant]
Calucho et al., “Correlation between SMA type and SMN2 copy No. revisited: an analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases,” Neuromuscular Disorders 28.3 (2018): 208-215.
[cited by applicant]
Campbell et al., “Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: results of a randomized, placebo-controlled clinical trial,” Muscle & nerve 55.4 (2017): 458-464.
[cited by applicant]
Cances et al., “Natural history of type 1 spinal muscular atrophy: a retrospective, global, multicenter study,” Orphanet Journal of Rare Diseases 17.1 (2022): 1-11.
[cited by applicant]
Cava et al., “Preserving healthy muscle during weight loss,” Advances in nutrition 8.3 (2017): 511-519.
[cited by applicant]
Cavagnaro, J., “Preclinical safety evaluation of biotechnology-derived pharmaceuticals,” Nature Reviews Drug Discovery 1.6 (2002): 469-475.
[cited by applicant]
Cedarbaum et al., “The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. Bdnf Als Study Group (Phase III),” Journal of the neurological sciences 169.1-2 (1999): 13-21.
[cited by applicant]
Chen et al., “The development and validation of a dysphagia-specific quality-of-life questionnaire for patients with head and neck cancer: the MD Anderson dysphagia inventory,” Archives of Otolaryngology-Head & Neck Sur…
[cited by applicant]
Chiriboga et al., “Longer-Term treatment with nusinersen: results in Later-onset spinal muscular atrophy from the shine study (1661),” Neurology 94.15 Supplement (2020): 1-3.
[cited by applicant]
Chiriboga et al., “Results from a phase 1 study of nusinersen (ISIS-SMNRx) in children with spinal muscular atrophy,” Neurology 86.10 (2016): 890-897.
[cited by applicant]
Chitramuthu et al., “Progranulin modulates zebrafish motoneuron development in vivo and rescues truncation defects associated with knockdown of Survival motor neuron 1,” Molecular neurodegeneration 5 (2010): 1-13.
[cited by applicant]
Clackson et al., “Making antibody fragments using phage display libraries,” Nature 352.6336 (1991): 624- 628.
[cited by applicant]
Coratti et al., “Age and baseline values predict 12 and 24-month functional changes in type 2 SMA,” Neuromuscular Disorders 30.9 (2020): 756-764.
[cited by applicant]
Coratti et al., “Clinical variability in spinal muscular atrophy type III,” Annals of neurology 88.6 (2020): 1109- 1117.
[cited by applicant]
Cornell, S., “A review of GLP-1 receptor agonists in type 2 diabetes: a focus on the mechanism of action of once-weekly agents,” Journal of clinical pharmacy and therapeutics 45 (2020): 17-27.
[cited by applicant]
Cote et al., “A sensitive and selective immunoassay for the quantitation of serum latent myostatin after in vivo administration of SRK-015, a selective inhibitor of myostatin activation,” Slas Discovery: Advancing Life …
[cited by applicant]
Crawford et al., “Apitegromab in SMA: An Analysis of Multiple Endpoints and PD Relationships to Efficacy in the TOPAZ Trial,” Annual Congress of the World Muscle Society (Sep. 20, 2021), 1 pg.
[cited by applicant]
Crawford et al., “TOPAZ extension: 24 month efficacy and safety of apitegromab in patients with later- onset Spinal Muscular Atrophy (type 2 and type 3 SMA),” presented at Cure SMA, Jun. 2022, 17 pages.
[cited by applicant]
Dankbar et al., “Myostatin-a new player in inflammatory bone loss,” Annals of the Rheumatic Diseases 70.Suppl 2 (2011): A75-A76.
[cited by applicant]
Darras et al., “Nusinersen in later-onset spinal muscular atrophy: long-term results from the phase 1/2 studies,” Neurology 92.21 (2019): e2492-e2506.
[cited by applicant]
Darras et al., “Risdiplam-treated infants with type 1 spinal muscular atrophy versus historical controls,” New England Journal of Medicine 385.5 (2021): 427-435.
[cited by applicant]
David et al., “Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells,” Blood 109.5 (2007): 1953-1961.
[cited by applicant]
Day et al., “Advances and limitations for the treatment of spinal muscular atrophy,” BMC pediatrics 22.1 (2022): 1-15.
[cited by applicant]
De Onis et al., “The WHO Multicentre Growth Reference Study: planning, study design, and methodology,” Food and nutrition bulletin 25 (2004): S15-S26.
[cited by applicant]